We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
Cap. Flow
+$34M
Cap. Flow %
12.86%
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45

Top Buys

Rank Stock Value
1
DTM icon
DT Midstream
DTM
+$1.85M
2
DK icon
Delek US
DK
+$898K
3
SMG icon
ScottsMiracle-Gro
SMG
+$843K
4
VLO icon
Valero Energy
VLO
+$783K
5
FMC icon
FMC
FMC
+$709K

Top Sells

Rank Stock Value
1
COR
Coresite Realty Corporation
COR
+$1.67M
2
XLRN
Acceleron Pharma
XLRN
+$601K
3
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$448K
5
TVTX icon
Travere Therapeutics
TVTX
+$434K

Sector Composition

Rank Sector Weight
1 Real Estate 22.39%
2 Healthcare 18.38%
3 Energy 15.88%
4 Materials 14.07%
5 Utilities 13.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSTX
401
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-23,082
Closed -$168K
DCPH
402
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-12,686
Closed -$431K
GMDA
403
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-33,121
Closed -$130K
BCEL
404
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-20,473
Closed -$128K
ORTX
405
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-4,226
Closed -$97K
ICPT
406
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-21,387
Closed -$318K
PRTK
407
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-20,379
Closed -$99K
HARP
408
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-1,377
Closed -$109K
MTEM
409
DELISTED
Molecular Templates, Inc.
MTEM
– –
-1,587
Closed -$160K
TCRR
410
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-11,762
Closed -$100K
CDAK
411
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-8,316
Closed -$136K
ALBO
412
DELISTED
Albireo Pharma Inc
ALBO
– –
-6,197
Closed -$193K
ATNX
413
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-2,072
Closed -$125K
RDUS
414
DELISTED
Radius Health, Inc.
RDUS
– –
-24,375
Closed -$302K
EPZM
415
DELISTED
Epizyme, Inc
EPZM
– –
-51,919
Closed -$266K
DRNA
416
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-5,581
Closed -$113K
COR
417
DELISTED
Coresite Realty Corporation
COR
– –
-12,058
Closed -$1.67M
FIV
418
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
– –
-23,625
Closed -$228K
XLRN
419
DELISTED
Acceleron Pharma
XLRN
– –
-3,490
Closed -$601K
KDMN
420
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-51,476
Closed -$448K
VTA
421
DELISTED
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
– –
-47,118
Closed -$551K
13 14 15 16
17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.

By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.

  • Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
  • Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
  • Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
  • Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
  • Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
  • Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
  • Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.